)
)
)
ProMIS Neurosciences (Nasdaq:PMN)
March 02, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
CNS/Neurological
ProMIS is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases. PMN310, the Company’s lead product candidate for the treatment of Alzheimer's disease, is a humanized monoclonal antibody that has been designed to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing, or eliminating amyloid-related imaging abnormalities (ARIA) liability. In addition, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed therapeutics. PMN310 was granted Fast Track designation by the FDA.
Year Founded:
2015
Lead Product in Development:
PMN310
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
